Molex to pick up drug and device packager Phillips-Medisize

Molex will acquire drug and device packaging company Phillips-Medisize in a deal that is expected to close this fall. Financial terms were not disclosed.

Hudson, WI-based Phillips-Medisize caters to the diagnostics and medical device, primary pharmaceutical and drug delivery sectors. It manufactures components for devices such as insulin pens and pumps, glucose meters and surgical tools for laparoscopic and endoscopic procedures, as well as pharmaceutical packaging.

A portfolio company of Golden State Capital, Phillips-Medisize has about 4,300 employees in 17 locations in North America, Europe and China. Of its $700 million in annual sales, 80% comes from drug delivery, medical device and diagnostic products. Meanwhile, Molex bills itself as a global manufacturer of “complete interconnect solutions.” Its products include lighting products, packaging and fiber optic systems.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“Molex’s global scale in electronics, coupled with Phillips-Medisize’s strength in designing and manufacturing innovative products for medical device customers, will help us become a global leader in connected health solutions,” said Phillips-Medisize CEO Matt Jennings in the statement.

Before being acquired itself, Phillips-Medisize made some deals of its own. In 2016 alone, it acquired Injectronics, which offers contract engineering and manufacturing services to diagnostics and medical device companies, as well as healthcare company Medicom.

- here's the statement

Related Article:
Phillips-Medisize buys Denmark’s Medicom Innovation, expanding European presence

Suggested Articles

Philips is cementing its commitment to becoming a healthcare technology provider, with plans to split off or sell its consumer appliances division.

A new digital health startup is exiting stealth mode with its advanced, long-lasting patient monitoring device—and touting a quick FDA clearance.

The FDA granted an expanded indication to GT Medical’s GammaTile cancer therapy, broadening its use to newly diagnosed brain cancer patients.